Recent data suggest that comorbid substance use disorders (SUDs) are common among chronic non-cancer pain (CNCP) patients; however, prevalence rates vary across studies and findings are limited regarding treatment options for CNCP patients with comorbid SUD. The purpose of this systematic review is to assess the prevalence, associated demographic and clinical characteristics, and treatment outcomes for CNCP patients with comorbid SUD. We conducted searches from Ovid MEDLINE, PsychINFO, and PubMED from 1950 through February 2010 and retrieved the references. Thirty-eight studies met inclusion criteria and provided data that addressed our key questions. Three to forty-eight percent of CNCP patients have a current SUD. There are no demographic or clinical factors that consistently differentiate CNCP patients with comorbid SUD from patients without SUD, though SUD patients appear to be at greater risk for aberrant medication-related behaviors. CNCP patients with SUD are more likely to be prescribed opioid medications and at higher doses than CNCP patients without a history of SUD. CNCP patients with comorbid SUD do not significantly differ in their responses to treatment compared to CNCP patients without SUD, though the quality of this evidence is low. Limited data are available to identify predictors of treatment outcome. Although clinical experience and research suggests that SUDs are common among CNCP patients, only limited data are available to guide clinicians who treat this population. Research is needed to increase understanding of the prevalence, correlates, and responses to treatment of CNCP patients with comorbid SUDs.
Introduction
An expanding empirical literature suggests that chronic noncancer pain (CNCP) is often comorbid with substance use disorders (SUD). Recent studies indicate that CNCP is common among patients being treated for SUD [18, 20] and history of SUD occurs frequently among patients who receive treatment for CNCP [37, 51] . However, the prevalence rates reported in recent studies have varied substantially, as has methodological rigor.
It is generally not understood how best to treat CNCP among patients with comorbid SUD, as little empirical data are available to guide interventions. Providers may be concerned about prescribing opioid medications to patients with SUD history due to concerns of misuse, addiction, or diversion [5, 27] . Additionally, patients with a history of SUD may be more resistant to traditional interventions due to increased tolerance to opioid medications, comorbid psychopathology, or other factors [3, 19] . Because prior chronic pain research studies have typically excluded patients with a history of SUD [14, 15] , there is little information available regarding the effectiveness of interventions to treat chronic pain in this population, a population which may be at risk for poorer pain treatment outcomes.
Recent systematic reviews have examined the prevalence of SUD among patients receiving opioid medications for chronic back pain [53] and the proportion of CNCP patients prescribed opioids who develop abuse or aberrant drug-related behaviors [7] . Although these reviews provide key information regarding the prevalence of SUD among CNCP patients taking opioids and the safety of prescribing opioids; they do not directly compare risk or pain treatment outcomes based on SUD status. Since clinicians may make key treatment decisions based on history of SUD [5], additional information is needed about the safety and efficacy of interventions for patients with pain and comorbid SUD.
